Investigating how cell-free hemoglobin affects lung injury during sepsis
Official title: Cell-free hemoglobin-oxidized LDL-LOX-1 axis and microvascular hyperpermeability during sepsis
Funded at University of South Alabama · NIH-11127820 · Data updated 2026-11-12
This study is looking at how a substance called cell-free hemoglobin can harm the lungs in people with sepsis, which might help us find new ways to treat lung problems like ARDS.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Alabama NIH-funded |
| Lab location | 1 site (Mobile, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $249,000 |
| NIH project number | 4R00HL166865-02 |
| Project ID | NIH-11127820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with sepsis who are at risk of developing acute respiratory distress syndrome.
✕Less likely to help
Patients who do not have sepsis or are not at risk for ARDS may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms by which cell-free hemoglobin contributes to lung injury in patients with sepsis. It examines how this hemoglobin interacts with low-density lipoprotein to disrupt the barrier of microvascular endothelial cells, leading to increased permeability and acute respiratory distress syndrome (ARDS). By analyzing patient samples, the study aims to uncover the cellular and molecular pathways involved in this process, potentially identifying new targets for treatment. The approach combines clinical data with laboratory analysis to explore these interactions in depth.
Why it matters
Potential benefit: If successful, this research could lead to new prevention or treatment strategies for ARDS in sepsis patients.
How similar studies have gone: While the specific mechanisms being investigated are novel, previous research has shown that targeting similar pathways can lead to significant advancements in treating sepsis-related complications.
Where this research is happening
-
University of South Alabama
Mobile, United States Active
Researchers
- Principal investigator: Meegan, Jamie E — University of South Alabama
- Study coordinator: Meegan, Jamie E
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.